432.17
2.35 (0.55%)
| Penutupan Terdahulu | 429.82 |
| Buka | 432.43 |
| Jumlah Dagangan | 1,110,066 |
| Purata Dagangan (3B) | 1,495,364 |
| Modal Pasaran | 110,804,353,024 |
| Harga / Pendapatan (P/E TTM) | 30.39 |
| Harga / Pendapatan (P/E Ke hadapan) | 23.98 |
| Harga / Jualan (P/S) | 10.08 |
| Harga / Buku (P/B) | 6.70 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Nov 2025 |
| Margin Keuntungan | -8.91% |
| Margin Operasi (TTM) | 37.22% |
| EPS Cair (TTM) | -3.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 3.00% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -41.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.00% |
| Nisbah Semasa (MRQ) | 2.65 |
| Aliran Tunai Operasi (OCF TTM) | -980.30 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 2.63 B |
| Pulangan Atas Aset (ROA TTM) | 11.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -5.64% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Vertex Pharmaceuticals Incorpor | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 2.00 |
|
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Large Value |
| % Dimiliki oleh Orang Dalam | 0.15% |
| % Dimiliki oleh Institusi | 97.64% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 575.00 (Citigroup, 33.05%) | Beli |
| Median | 475.00 (9.91%) | |
| Rendah | 414.00 (Barclays, -4.20%) | Pegang |
| Purata | 491.11 (13.64%) | |
| Jumlah | 6 Beli, 3 Pegang | |
| Harga Purata @ Panggilan | 415.68 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 05 Dec 2025 | 564.00 (30.50%) | Beli | 457.36 |
| 03 Dec 2025 | 516.00 (19.40%) | Beli | 463.13 | |
| UBS | 07 Nov 2025 | 546.00 (26.34%) | Beli | 409.47 |
| Barclays | 04 Nov 2025 | 414.00 (-4.20%) | Pegang | 421.67 |
| RBC Capital | 04 Nov 2025 | 415.00 (-3.97%) | Pegang | 421.67 |
| Stifel | 04 Nov 2025 | 445.00 (2.97%) | Pegang | 421.67 |
| JP Morgan | 08 Oct 2025 | 530.00 (22.64%) | Beli | 421.15 |
| Citigroup | 02 Oct 2025 | 575.00 (33.05%) | Beli | 408.85 |
| Leerink Partners | 25 Sep 2025 | 456.00 (5.51%) | Beli | 381.87 |
| Evercore ISI Group | 11 Sep 2025 | 475.00 (9.91%) | Beli | 397.37 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |